浅谈靶向联合免疫检查点抑制剂在HER2阳性进展期胃癌研究进展：从基础到临床
Research Progress of Targeted Combined Immunization in HER2 Positive Advanced Gastric Cancer: From Bench to Bedside
DOI: 10.12677/ACM.2023.134828, PDF,   
作者: 张 雪：青岛大学医学部，山东 青岛；赵丽丽：青岛市中医医院(市海慈医院)，青岛大学附属青岛市海慈医院，山东 青岛；井文君, 于晓鹏, 杨 帅, 魏红梅*：青岛大学附属青岛市中心医院，青岛市肿瘤医院，山东 青岛
关键词: 胃癌；靶向治疗；免疫治疗；HER2；PD-L1；Gastric Cancer； Targeted Therapy； Immunotherapy； HER2； PD-L1
摘要: 在中国，胃癌的发病率与死亡率均排名第三，疾病负担重。HER2阳性胃癌是胃癌的重要亚型，靶向HER2的曲妥珠单抗联合化疗能显著改善进展期胃癌患者的预后，并已成为此类晚期胃癌的一线标准治疗。免疫检查点抑制剂为主的免疫治疗是肿瘤治疗领域的研究热点，但目前临床主要应用在HER2阴性进展期胃癌中。为进一步改善HER2阳性胃癌患者预后，抗HER2靶向联合免疫检查点抑制剂在HER2阳性进展期胃癌患者中获得了初步的疗效，提示HER2阳性进展期胃癌抗HER2靶向联合免疫检查点抑制剂治疗具有深入探讨的价值。本文将现有的进展期HER2阳性胃癌主要的治疗手段——抗HER2靶向治疗以及联合免疫治疗方面，整合了临床前研究与相关临床研究的数据，对HER2阳性进展期胃癌靶向、靶向联合免疫治疗的相关研究作一综述，展望HER2阳性进展期胃癌治疗前景及方向。
Abstract: The incidence rate and mortality of gastric cancer rank third in China, and the disease burden is heavy. HER2 positive gastric cancer is an important subtype of gastric cancer. Trastuzumab target-ing HER2 combined with chemotherapy can significantly improve the prognosis of patients with advanced gastric cancer, and has become the first-line standard treatment of this kind of advanced gastric cancer. Immunotherapy based on immune checkpoint inhibitors is a research hotspot in the field of tumor therapy, but at present, it is mainly used in HER2 negative advanced gastric cancer. In order to further improve the prognosis of patients with HER2 positive gastric cancer, anti-HER2 targeted combined with immune checkpoint inhibitor has achieved preliminary curative effect in patients with HER2 positive advanced gastric cancer, suggesting that the treatment of anti-HER2 targeted combined with immune checkpoint inhibitor for HER2 positive advanced gastric cancer has the value of in-depth discussion. In this paper, the existing main treatment methods of ad-vanced HER2 positive gastric cancer-anti HER2 targeted therapy and combined immunotherapy, integrate the data of preclinical research and relevant clinical research, summarize the related re-search of HER2 positive advanced gastric cancer targeting and targeted combined immunotherapy, and look forward to the prospect and direction of HER2 positive advanced gastric cancer treatment.
文章引用：张雪, 赵丽丽, 井文君, 于晓鹏, 杨帅, 魏红梅. 浅谈靶向联合免疫检查点抑制剂在HER2阳性进展期胃癌研究进展：从基础到临床[J]. 临床医学进展, 2023, 13(4): 5864-5871. https://doi.org/10.12677/ACM.2023.134828

参考文献

[1] WHO (n.d.) Globocan 2020.
https://gco.iarc.fr/today/data/factsheets/populations/160-china-fact-sheets
[2] Chi-arello, M.M., Fico, V., Pepe, G., et al. (2022) Early Gastric Cancer: A Challenge in Western Countries. World Journal of Gastroenterology, 28, 693-703. [Google Scholar] [CrossRef] [PubMed]
[3] Correa, P. (2013) Gastric Cancer: Overview. Gastroenterology Clinics of North America, 42, 211-217. [Google Scholar] [CrossRef] [PubMed]
[4] Bang, Y.-J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Ad-vanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet, 376, 687-697. [Google Scholar] [CrossRef] 
[5] Joshi, S.S. and Badgwell, B.D. (2021) Current Treatment and Recent Progress in Gastric Cancer. CA: A Cancer Journal for Clinicians, 71, 264-279. [Google Scholar] [CrossRef] [PubMed]
[6] Lordick, F., Kang, Y.-K., Chung, H.C., et al. (2013) Capecitabine and Cis-platin with or without Cetuximab for Patients with Previously Untreated Advanced Gastric Cancer (EXPAND): A Ran-domised, Open-Label Phase 3 Trial. The Lancet Oncology, 14, 490-499. [Google Scholar] [CrossRef] 
[7] 潘云枫, 刘宝瑞, 魏嘉. HER2阳性胃癌免疫治疗的研究进展[J]. 中国肿瘤生物治疗杂志, 2021, 28(1): 90-96.
[8] 刘辉, 施俊. 晚期胃癌治疗的研究进展[J]. 现代肿瘤医学, 2021, 29(23): 4226-4229.
[9] Chung, H.C., Bang, Y.J., Fuchs, C.S., et al. (2021) First-Line Pembroli-zumab/Placebo plus Trastuzumab and Chemotherapy in HER2-Positive Advanced Gastric Cancer: KEYNOTE-811. Fu-ture Medicine, 17, 491-501. [Google Scholar] [CrossRef] [PubMed]
[10] Gerson, J.N., Skariah, S., Denlinger, C.S. and Astsaturov, I. (2017) Perspectives of HER2-Targeting in Gastric and Esophageal Cancer. Expert Opinion on Investigational Drugs, 26, 531-540. [Google Scholar] [CrossRef] [PubMed]
[11] Moasser, M.M. (2007) The Oncogene HER2: Its Signaling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. [Google Scholar] [CrossRef] [PubMed]
[12] Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. [Google Scholar] [CrossRef] [PubMed]
[13] Singh, D., Attri, B.K., Gill, R.K. and Bariwal, J. (2016) Review on EGFR Inhibitors: Critical Updates. Mini-Reviews in Medicinal Chemistry, 16, 1134-1166. [Google Scholar] [CrossRef] [PubMed]
[14] Meric-Bernstam, F., Johnson, A.M., Dumbrava, E.E.I., et al. (2019) Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 25, 2033-2041. [Google Scholar] [CrossRef] 
[15] Holbro, T., Beerli, R.R., Maurer, F., et al. (2003) The ErbB2/ErbB3 Heterodimer Functions as an Oncogenic Unit: ErbB2 Requires ErbB3 to Drive Breast Tumor Cell Prolifer-ation. Proceedings of the National Academy of Sciences of the United States of America, 100, 8933-8938. [Google Scholar] [CrossRef] [PubMed]
[16] Shabbir, A., Qureshi, M.A., Mirza, T. and Khalid, A.B. (2017) Human Epidermal Growth Factor (Her-2) in Gastric and Colorectal Adenocarcinoma. The Journal of Pakistan Medical Association, 67, 1085-1090.
[17] Kanayama, K., Imai, H., Usugi, E., et al. (2018) Association of HER2 Gene Amplifi-cation and Tumor Progression in Early Gastric Cancer. Virchows Archiv, 473, 559-565. [Google Scholar] [CrossRef] [PubMed]
[18] Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987) Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. Science, 235, 177-182. [Google Scholar] [CrossRef] [PubMed]
[19] Shitara, K., Yatabe, Y., Matsuo, K., et al. (2013) Prognosis of Patients with Advanced Gastric Cancer by HER2 Status and Trastuzumab Treatment. Gastric Cancer, 16, 261-267. [Google Scholar] [CrossRef] [PubMed]
[20] Yaziji, H., Goldstein, L.C., Barry, T.S., et al. (2004) HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods. JAMA, 291, 1972-1977. [Google Scholar] [CrossRef] [PubMed]
[21] 刘文杰, 吴菡, 黄建, 周武碧. 人类表皮生长因子受体2对胃癌细胞增殖、迁移侵袭和凋亡的影响[J]. 安徽医药, 2021, 25(2): 299-303+426.
[22] Gravalos, C. and Jimeno, A. (2008) HER2 in Gastric Cancer: A New Prognostic Factor and a Novel Therapeutic Target. Annals of Oncology, 19, 1523-1529. [Google Scholar] [CrossRef] [PubMed]
[23] Park, D.I., Yun, J.W., Park, J.H., et al. (2006) HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences, 51, 1371-1379. [Google Scholar] [CrossRef] [PubMed]
[24] 王龙, 刘巍. 进展期胃癌的分子靶向治疗进展[J]. 临床肿瘤学杂志, 2010, 15(9): 856-860.
[25] 李龙, 展昊, 龙勃, 等. 曲妥珠单抗联合化疗治疗HER-2阳性晚期胃癌的Meta分析[J]. 中国循证医学杂志, 2017, 17(1): 40-46.
[26] 沈琳, 徐建明, 冯奉仪, 等. 曲妥珠单抗联合化疗一线治疗人表皮生长因子受体2阳性无法手术的局部进展期或转移性胃或胃食管结合部腺癌的多中心随机对照Ⅲ期临床试验中国亚组报告[J]. 中华肿瘤杂志, 2013, 35(4): 295-300.
[27] Wang, F., Liu, T.-S., Yuan, X.-L., et al. (2020) Trastuzumab PLus Docetaxel and Capecitabine as a First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: A Phase II, Multicenter, Open-Label, Single-Arm Study. American Journal of Can-cer Research, 10, 3037-3046.
[28] ter Veer, E., van den Ende, T., Creemers, A., et al. (2018) Continuation of Trastuzumab beyond Progression in HER2- Positive Advanced Esophagogastric Cancer: A Meta-Analysis. Acta Onco-logica, 57, 1599-1604. [Google Scholar] [CrossRef] 
[29] 朱逸晖, 李婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[30] 程浩, 依荷芭丽•迟, 石素胜. 抗体偶联药物治疗消化系统肿瘤的研究进展[J]. 现代肿瘤医学, 2022, 30(5): 916-922.
[31] Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 Ligands: From Discovery to Clinical Application. International Immunology, 19, 813-824. [Google Scholar] [CrossRef] [PubMed]
[32] Cui, C., Yu, B., Jiang, Q., et al. (2019) The Roles of PD-1/PD-L1 and Its Signalling Pathway in Gastrointestinal Tract Cancers. Clinical and Experimental Pharmacology and Physiology, 46, 3-10. [Google Scholar] [CrossRef] [PubMed]
[33] Pardoll, D.M. (2012) The Blockade of Im-mune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[34] Sliwkowski, M.X., Lofgren, J.A., Lewis, G.D., et al. (1999) Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin). Seminars in Oncology, 26, 60-70.
[35] Yamazaki, T., Akiba, H., Iwai, H., et al. (2002) Expression of Programmed Death 1 Ligands by Murine T Cells and APC. The Journal of Immunology, 169, 5538-5545. [Google Scholar] [CrossRef] [PubMed]
[36] Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q., Tang, L., Yang, W. and Wang, H. (2021) NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metabolism, 33, 110-127.e5. [Google Scholar] [CrossRef] [PubMed]
[37] Kono, K., Takahashi, A., Ichihara, F., et al. (2002) Impaired An-tibody-Dependent Cellular Cytotoxicity Mediated by Herceptin in Patients with Gastric Cancer. Cancer Research, 62, 5813-5817.
[38] Alspach, E., Lussier, D.M. and Schreiber, R.D. (2019) Interferon γ and Its Important Roles in Pro-moting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harbor Perspectives in Biology, 11, a028480. [Google Scholar] [CrossRef] [PubMed]
[39] Chaganty, B.K.R., Qiu, S., Gest, A., et al. (2018) Trastuzumab Upregulates PD-L1 as a Potential Mechanism of Trastuzumab Resistance through Engagement of Immune Effector Cells and Stimulation of IFNγ Secretion. Cancer Letters, 430, 47-56. [Google Scholar] [CrossRef] [PubMed]
[40] Yamashita, K., Iwatsuki, M., Yasuda-Yoshihara, N., et al. (2021) Trastuzumab Upregulates Programmed Death Ligand-1 Expression through Interaction with NK Cells in Gastric Cancer. British Journal of Cancer, 124, 595-603. [Google Scholar] [CrossRef] [PubMed]
[41] Iwata, T.N., Ishii, C., Ishida, S., et al. (2018) A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Molecular Cancer Therapeutics, 17, 1494-1503. [Google Scholar] [CrossRef] [PubMed]
[42] Nordstrom, J.L., Gorlatov, S., Zhang, W., et al. (2011) An-ti-Tumor Activity and Toxicokinetics Analysis of MGAH22, an Anti-HER2 Monoclonal Antibody with Enhanced Fcγ Receptor Binding Properties. Breast Cancer Research, 13, Article No. R123. [Google Scholar] [CrossRef] [PubMed]
[43] Bang, Y.J., Giaccone, G., Im, S.A., et al. (2017) First-in-Human Phase 1 Study of Margetuximab (MGAH22), an Fc-Modified Chimeric Monoclonal Antibody, in Patients with HER2-Positive Advanced Solid Tumors. Annals of Oncology, 28, 855-861. [Google Scholar] [CrossRef] [PubMed]
[44] Taylor, C., Hershman, D., Shah N, et al. (2007) Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research, 13, 5133-5143. [Google Scholar] [CrossRef] 
[45] Janjigian, Y.Y., Maron, S.B., Chatila, W.K., et al. (2020) First-Line Pembrolizumab and Trastuzumab in HER2-Positive Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: An Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 821-831. [Google Scholar] [CrossRef] 
[46] Strong, V.E. (2018) Progress in Gastric Cancer. Updates in Surgery, 70, 157-159. [Google Scholar] [CrossRef] [PubMed]
[47] Catenacci, D.V.T., Kang, Y.K., Park, H., et al. (2020) Margetux-imab plus Pembrolizumab in Patients with Previously Treated, HER2-Positive Gastro-Oesophageal Adenocarcinoma (CP-MGAH22-05): A Single-Arm, Phase 1b-2 Trial. The Lancet Oncology, 21, 1066-1076. [Google Scholar] [CrossRef] 
[48] Tian, X., Zhu, Q. and Zhang, Z. (2021) Durable Clinical Re-sponse to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review. OncoTargets and Therapy, 14, 3701-3708. [Google Scholar] [CrossRef] 

为你推荐